[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20100693T1 - Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora - Google Patents

Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora Download PDF

Info

Publication number
HRP20100693T1
HRP20100693T1 HR20100693T HRP20100693T HRP20100693T1 HR P20100693 T1 HRP20100693 T1 HR P20100693T1 HR 20100693 T HR20100693 T HR 20100693T HR P20100693 T HRP20100693 T HR P20100693T HR P20100693 T1 HRP20100693 T1 HR P20100693T1
Authority
HR
Croatia
Prior art keywords
azonia
bicyclo
hydroxy
octane bromide
acetoxy
Prior art date
Application number
HR20100693T
Other languages
English (en)
Croatian (hr)
Inventor
John Press Neil
Paul Collingwood Stephen
Baettig Urs
Cox Brian
Devidasrao Garad Sudhakar
Kim Hyungchul
Papoutsakis Dimitris
James Watson Simon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33515948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100693(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20100693T1 publication Critical patent/HRP20100693T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20100693T 2004-11-02 2005-10-31 Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora HRP20100693T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0424284.8A GB0424284D0 (en) 2004-11-02 2004-11-02 Organic compounds
PCT/EP2005/011662 WO2006048225A1 (en) 2004-11-02 2005-10-31 Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20100693T1 true HRP20100693T1 (hr) 2011-01-31

Family

ID=33515948

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100693T HRP20100693T1 (hr) 2004-11-02 2005-10-31 Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora

Country Status (33)

Country Link
US (2) US7723356B2 (es)
EP (2) EP2206499A1 (es)
JP (1) JP4950896B2 (es)
KR (1) KR101252307B1 (es)
CN (1) CN101056634B (es)
AR (1) AR054090A1 (es)
AT (1) ATE481099T1 (es)
AU (1) AU2005300710B2 (es)
BR (1) BRPI0517945A (es)
CA (1) CA2583237C (es)
CY (1) CY1110952T1 (es)
DE (1) DE602005023639D1 (es)
DK (1) DK1811999T3 (es)
EC (1) ECSP077424A (es)
ES (1) ES2353142T3 (es)
GB (1) GB0424284D0 (es)
HR (1) HRP20100693T1 (es)
IL (1) IL182695A0 (es)
JO (1) JO2613B1 (es)
MA (1) MA29080B1 (es)
MX (1) MX2007005189A (es)
MY (1) MY145207A (es)
NO (1) NO20072371L (es)
NZ (1) NZ554302A (es)
PE (1) PE20060609A1 (es)
PL (1) PL1811999T3 (es)
PT (1) PT1811999E (es)
RU (1) RU2399620C2 (es)
SI (1) SI1811999T1 (es)
TN (1) TNSN07164A1 (es)
TW (1) TW200628154A (es)
WO (1) WO2006048225A1 (es)
ZA (1) ZA200702772B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
EP1940775A2 (en) * 2005-08-11 2008-07-09 University of Massachusetts Methods and compositions for the efficient delivery of therapeutic agents to cells and animals
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
MX2009006018A (es) * 2006-12-19 2009-06-16 Astrazeneca Ab Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
HRP20110938T1 (hr) 2007-09-07 2012-01-31 Theravance Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
JP4837800B2 (ja) 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
CA2723909A1 (en) * 2008-05-13 2009-11-19 Richard James Bull Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
US20090326004A1 (en) * 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2009153536A1 (en) * 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
AU2010233772B2 (en) 2009-04-09 2014-04-24 Novartis Ag Process for preparing pyrrolidinium salts
BR112012032333A2 (pt) * 2010-06-22 2016-11-08 Chiesi Farma Spa composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
KR20130111967A (ko) * 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 항무스카린성 약물을 포함하는 건조 분말 제제
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
CA2895448A1 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
EP3134398A1 (en) 2014-04-24 2017-03-01 Novartis Ag Autotaxin inhibitors
CA2944714C (en) * 2014-05-06 2023-05-16 Anthony G. Visco Methods of treating or preventing preterm labor
CN109851615B (zh) * 2019-04-22 2021-06-08 上海旭东海普药业有限公司 纯化戊乙奎醚的方法

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833592A (en) 1966-05-31 1974-09-03 Little Inc A Tropanyl alpha,alpha-diphenyl-alpha-fluoroacetate esters
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
GB9119705D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
DE69331265T2 (de) 1992-04-02 2002-08-08 Smithkline Beecham Corp., Philadelphia Verbindungen zur behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
NZ251092A (en) 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9617730D0 (en) 1996-08-23 1996-10-02 Pfizer Ltd Quarternary ammonium compounds
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
TR200100410T2 (tr) 1998-06-23 2001-06-21 Glaxo Group Limited 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri.
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
BR9815931A (pt) 1998-06-30 2001-02-20 Dow Chemical Co Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida
ATE331726T1 (de) 1998-10-16 2006-07-15 Pfizer Adenine-derivate
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CA2381802C (en) 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of roflumilast and salmeterol
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
YU79502A (sh) 2000-04-27 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Novi,sporodelujući betamimetici,postupak za njihovo pripremanje i njihova primena kao lekova
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
UA72632C2 (uk) * 2000-06-27 2005-03-15 Лабораторіос С.А.Л.В.А.Т., С.А. Карбамати, похідні від арилалкіламінів
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
AP1422A (en) 2000-08-05 2005-06-05 Glaxo Group Ltd 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent.
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
AU2001284646A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
US6476222B2 (en) 2001-01-05 2002-11-05 Sun Chemical Corporation Preparation of heat stable pigment violet 23
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
KR100831534B1 (ko) 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
AP2003002911A0 (en) 2001-05-25 2003-12-31 Pfizer An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
CN1585633B (zh) 2001-09-14 2010-10-27 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
EP1461336B1 (en) 2001-12-20 2013-05-22 CHIESI FARMACEUTICI S.p.A. 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
AU2003202044A1 (en) 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
RS51097B (sr) 2002-03-26 2010-10-31 Boehringer Ingelheim Pharmaceuticals Inc. Glukokortikoidni mimetici,postupci za njihovo dobijanje, farmaceutski preparati i njihova primena
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2006515829A (ja) 2002-04-10 2006-06-08 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
DE60318193T2 (de) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ATE356808T1 (de) 2002-06-25 2007-04-15 Merck Frosst Canada Ltd 8-(biaryl)chinolin-pde4-inhibitoren
US20060004056A1 (en) 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
CN1671695A (zh) 2002-08-10 2005-09-21 奥坦纳医药公司 用作pde4抑制剂的吡咯烷二酮取代的哌啶－2,3－二氮杂萘酮化合物
WO2004018450A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
US20060167001A1 (en) 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
HRP20050228A2 (en) 2002-08-17 2006-07-31 Altana Pharma Ag Novel phenanthridines
JP2005537313A (ja) 2002-08-17 2005-12-08 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のベンゾナフチリジン
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7329676B2 (en) 2002-08-29 2008-02-12 Nycomed Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
RS20050174A (en) 2002-08-29 2007-06-04 Boehringer Ingelheim Pharmaceuticals Inc., -3(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
US7423046B2 (en) 2002-08-29 2008-09-09 Nycomed Gmbh 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
EP1542996A4 (en) 2002-09-20 2009-11-18 Merck & Co Inc OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
ES2302938T3 (es) 2002-10-11 2008-08-01 Pfizer Inc. Derivados de indol como agonistas beta-2.
JP2006506373A (ja) 2002-10-22 2006-02-23 グラクソ　グループ　リミテッド 医薬アリールエタノールアミン化合物
MXPA05004432A (es) 2002-10-23 2005-11-23 Glenmark Pharmaceuticals Ltd Compuestos triciclicos novedosos utiles para el tratamiento de desordenes inflamatorios y alergicos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
CA2512987C (en) 2003-01-21 2011-06-14 Merck & Co., Inc. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
JP4516064B2 (ja) 2003-04-04 2010-08-04 ノバルティス アーゲー 気道疾患の処置のためのキノリン−２−オン誘導体
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
JP4616264B2 (ja) 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
ATE384697T1 (de) 2003-06-04 2008-02-15 Pfizer 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
DE10332239B3 (de) 2003-07-16 2005-03-03 Framatome Anp Gmbh Zirkoniumlegierung und Bauteile für den Kern von leichtwassergekühlten Kernreaktoren
WO2005033121A2 (en) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US7591941B2 (en) 2003-12-19 2009-09-22 Shell Oil Company Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (de) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
ES2246170B1 (es) 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.

Also Published As

Publication number Publication date
EP1811999B1 (en) 2010-09-15
CY1110952T1 (el) 2015-06-11
NZ554302A (en) 2009-12-24
JP2008518890A (ja) 2008-06-05
MY145207A (en) 2012-01-13
US20090048281A1 (en) 2009-02-19
CN101056634A (zh) 2007-10-17
EP1811999A1 (en) 2007-08-01
ECSP077424A (es) 2007-05-30
ES2353142T3 (es) 2011-02-25
CA2583237C (en) 2013-01-22
DE602005023639D1 (de) 2010-10-28
AU2005300710A1 (en) 2006-05-11
PT1811999E (pt) 2010-10-29
PL1811999T3 (pl) 2011-03-31
GB0424284D0 (en) 2004-12-01
RU2399620C2 (ru) 2010-09-20
BRPI0517945A (pt) 2008-10-21
SI1811999T1 (sl) 2011-01-31
KR20070073849A (ko) 2007-07-10
ZA200702772B (en) 2008-08-27
US8084463B2 (en) 2011-12-27
US20100168132A1 (en) 2010-07-01
TW200628154A (en) 2006-08-16
PE20060609A1 (es) 2006-08-21
MA29080B1 (fr) 2007-12-03
NO20072371L (no) 2007-07-12
US7723356B2 (en) 2010-05-25
MX2007005189A (es) 2007-05-11
EP2206499A1 (en) 2010-07-14
DK1811999T3 (da) 2010-12-13
ATE481099T1 (de) 2010-10-15
JP4950896B2 (ja) 2012-06-13
AR054090A1 (es) 2007-06-06
KR101252307B1 (ko) 2013-04-08
IL182695A0 (en) 2007-09-20
JO2613B1 (ar) 2011-11-01
AU2005300710B2 (en) 2009-05-14
CA2583237A1 (en) 2006-05-11
TNSN07164A1 (en) 2008-11-21
RU2007120454A (ru) 2008-12-10
WO2006048225A1 (en) 2006-05-11
CN101056634B (zh) 2011-11-30

Similar Documents

Publication Publication Date Title
HRP20100693T1 (hr) Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora
DK2960234T3 (en) TRK-INHIBITING CONNECTION
Rojas et al. Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis
ES2337241T3 (es) Derivados de piperazina con actividad antagonista de receptores ccr1.
JP7595413B2 (ja) １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
CN106573006A (zh) 作为药物的rip1激酶抑制剂杂环酰胺
KR20180022833A (ko) 항균성 화합물
TW200607807A (en) Macrocyclic beta-secretase inhibitors
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
CA2985366A1 (en) Methods of treating a neurodegenerative disease
CN113164490B (zh) 采用p2x3拮抗剂治疗瘙痒症
CN101454313A (zh) P38抑制剂及其使用方法
EP4121047A1 (en) Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
EP3022201A1 (en) Autotaxin inhibitors
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
Uto 1, 2-Benzisoxazole compounds: a patent review (2009–2014)
GB2516138A (en) The treatment of inflammatory disorders
CN105175304A (zh) 抗胆碱药物格隆溴铵及组合物
AU2018347447B2 (en) Methods and compositions for treating pruritus, xerosis, and associated disease using CCR3-inhibitors
Yang et al. Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists
CS277691A3 (en) 3-/1h-indazol-3-yl/-4-pyridinamines, process and intermediates for their preparation and their application as medicaments
SA05260389B1 (ar) فينيل ببرازين تجمع بين الميل إلى مستقبلات دوبامين d2- ومواضع اعادة امتصاص السيروتونين
TWI492920B (zh) 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
JPH03206038A (ja) 抗菌剤
EPT et al. Drug Design Strategies, Modes of Action, Synthesis and Industrial Challenges Behind Trifluoromethylated New Chemical Entities